Ireland

Key Insights

1
No psychedelic therapy is approved for routine patient access in Ireland; use remains tightly restricted to licensed clinical research and standard off-label prescribing rules.
2
Ireland’s database shows 13 trials, 2 active, across 4 research organisations; psilocybin and placebo dominate the active portfolio, with ketamine and 5-MeO-DMT also studied.
3
Trinity College Dublin hosted Ireland’s first psychedelic research conference on 25 October 2024, marking a visible national inflection point for the field.
4
Momentum is coming from Trinity’s Psychedelic Research Group and the Government’s 2026–2027 clinical-trials reforms, which will create a Clinical Trials Advisory Council by early 2026.

Medical Only (Private)

Reimbursed Care Access

Ireland maintains a largely prohibitionist statutory regime for classic psychedelics (psilocybin, MDMA, DMT, mescaline, 5-MeO-DMT, ibogaine, 2C‑X and sacramental preparations such as ayahuasca) where possession/supply is a criminal offence except under licence for research or other narrowly defined purposes. Separately, esketamine (Spravato®) is an authorised medicine in Ireland with a formal HTA/reimbursement process and has been made available under HSE arrangements following negotiation; ketamine remains a licensed anaesthetic (controlled drug) and is used off‑label by some clinicians/clinics for treatment-resistant depression, typically outside public reimbursement pathways.

Full guide →